Activity ID
15079Expires
July 30, 2027Format Type
EnduringCME Credit
0.5Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Schizophrenia.
ABMS Member Board Approvals by Type
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
Differentiate dopaminergic and muscarinic mechanisms of actions of novel therapies, and explain the clinical utility to address unmet needs of patients with schizophrenia
Evaluate emerging clinical evidence supporting novel therapies in schizophrenia, with attention to efficacy signals, safety considerations, and current limitations of the data
Design strategies to integrate novel therapeutic options into treatment plans for patients with schizophrenia while counseling them on optimal administration and side effect management
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
